semaglutide ckd trial — Blog — NephJC flow trial semaglutide kidney outcomes

The SURPASS clinical trial programme explored its effects in the context of type 2 diabetes research, with results that were widely described as groundbreaking

Here we develop a series of peptides closely related to the GLP-1 homolog exendin-4, used clinically as exenatide 12 , but with widely varying trafficking properties

The sections below cover each of these in depth so you can decide for yourself

Extensive cardiovascular outcome trials have demonstrated that certain GLP-1 receptor agonists can reduce cardiovascular risk

From a medical standpoint, the most important changes often show up in follow-up labs, where triglycerides and markers of inflammation may improve as visceral fat decreases

Patoulias D, Michailidis T, Dimosiari A, et al